- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
China Resources Double-Crane Pharmaceutical Co Ltd (600062)
China Resources Double-Crane Pharmaceutical Co Ltd stock price live, this page displays SS 600062 stock exchange data. View the 600062 premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the China Resources Double-Crane Pharmaceutical Co Ltd real time stock price chart below.
What Is the China Resources Double-Crane Pharmaceutical Co Ltd Stock Price Today?
The China Resources Double-Crane Pharmaceutical Co Ltd stock price today is 16.63.
What Is the Stock Symbol for China Resources Double-Crane Pharmaceutical Co Ltd?
The stock symbol for China Resources Double-Crane Pharmaceutical Co Ltd is "600062."
What Stock Exchange Does China Resources Double-Crane Pharmaceutical Co Ltd Trade On?
China Resources Double-Crane Pharmaceutical Co Ltd is listed and trades on the Shanghai stock exchange.
Is China Resources Double-Crane Pharmaceutical Co Ltd a Good Stock to Buy?
Determining whether China Resources Double-Crane Pharmaceutical Co Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 600062 quote. (ISIN: CNE000000Q94)
What Is the China Resources Double-Crane Pharmaceutical Co Ltd Stock Price Today?
The China Resources Double-Crane Pharmaceutical Co Ltd stock price today is 16.63.
What Is the Stock Symbol for China Resources Double-Crane Pharmaceutical Co Ltd?
The stock symbol for China Resources Double-Crane Pharmaceutical Co Ltd is "600062."
What Stock Exchange Does China Resources Double-Crane Pharmaceutical Co Ltd Trade On?
China Resources Double-Crane Pharmaceutical Co Ltd is listed and trades on the Shanghai stock exchange.
Is China Resources Double-Crane Pharmaceutical Co Ltd a Good Stock to Buy?
Determining whether China Resources Double-Crane Pharmaceutical Co Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 600062 quote. (ISIN: CNE000000Q94)
Shanghai
Currency in CNY
16.63
-0.48(-2.81%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
16.62
17.14
52 wk Range
15.29
22.14
600062 is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
16.6217.14
52 wk Range
15.2922.14
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(2.83%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(2.83%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
600062 Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
25.33
Upside
+52.29%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Prominent player in the Pharmaceuticals industry
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 25.33
(+52.29% Upside)
Earnings
Latest Release
Apr 25, 2026
EPS / Forecast
0.47 / --
Revenue / Forecast
2.81B / 12.36B
Compare 600062 to Peers and Sector
Metrics to compare | 600062 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship600062PeersSector | |
|---|---|---|---|---|
P/E Ratio | 10.9x | 26.2x | −0.3x | |
PEG Ratio | −24.74 | 0.28 | 0.00 | |
Price/Book | 1.5x | 2.7x | 2.6x | |
Price / LTM Sales | 1.6x | 3.2x | 3.0x | |
Upside (Analyst Target) | 49.9% | 37.2% | 55.4% | |
Fair Value Upside | Unlock | 18.8% | 8.8% | Unlock |
China Resources Double-Crane Pharmaceutical Co.,Ltd. operates as a pharmaceutical company in the People’s Republic of China. The company offers pharmaceutical products for blood pressure and sugar, injections, lipid-lowering, pediatrics, nephrology, API, pharmaceutical, psychiatry/neurology, inflammation, anticoagulation, oncology, women's health, anesthesia, and analgesia. The company was founded in 1939 and is headquartered in Beijing, the People’s Republic of China. China Resources Double-Crane Pharmaceutical Co.,Ltd. operates as a subsidiary of Beijing Pharmaceutical Group Co., Ltd.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the China Resources D-C Pharm (600062) Stock Price Today?
The China Resources D-C Pharm stock price today is 16.63 CNY.
What Stock Exchange Does China Resources D-C Pharm Trade On?
China Resources D-C Pharm is listed and trades on the Shanghai Stock Exchange.
What Is the Stock Symbol for China Resources D-C Pharm?
The stock symbol for China Resources D-C Pharm is "600062."
Does China Resources D-C Pharm Pay Dividends? What’s The Current Dividend Yield?
The China Resources D-C Pharm dividend yield is 2.83%.
What Is the China Resources D-C Pharm Market Cap?
As of today, China Resources D-C Pharm market cap is 17.18B CNY.
What Is China Resources D-C Pharm's Earnings Per Share (TTM)?
The China Resources D-C Pharm EPS (TTM) is 1.57.
When Is the Next China Resources D-C Pharm Earnings Date?
China Resources D-C Pharm will release its next earnings report on Aug 22, 2026.
From a Technical Analysis Perspective, Is 600062 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has China Resources D-C Pharm Stock Split?
China Resources D-C Pharm has split 8 times.
How Many Employees Does China Resources D-C Pharm Have?
China Resources D-C Pharm has 13184 employees.
What is the current trading status of China Resources D-C Pharm (600062)?
As of Jul 24, 2026, China Resources D-C Pharm (600062) is trading at a price of 16.63 CNY, with a previous close of 17.11 CNY. The stock has fluctuated within a day range of 16.62 CNY to 17.14 CNY, while its 52-week range spans from 15.29 CNY to 22.14 CNY.
What Is China Resources D-C Pharm (600062) Price Target According to Analysts?
The average 12-month price target for China Resources D-C Pharm is 25.33 CNY, with a high estimate of 25.65 CNY and a low estimate of 25 CNY. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +52.29% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.